infohep news

• Interferon treatment for HBV

  Adding pegylated interferon to tenofovir improves odds of HBsAg loss in hepatitis B patients

  Liz Highleyman / 05 February 2015

  People with chronic hepatitis B virus (HBV) infection are more likely to experience favourable treatment response, as indicated by hepatitis B surface antigen (HBsAg) loss, if they add pegylated interferon to tenofovir -- ...

• Antiviral therapy

  Entecavir and tenofovir work well for people with drug-resistant hepatitis B virus

  Liz Highleyman / 04 February 2015

  A combination of entecavir plus tenofovir effectively suppressed hepatitis B virus (HBV) in people with resistance to other antivirals, according to results from the European ENTEBE study presented at the American Association for ...

• Eligibility for treatment

  One million people with hepatitis C in the US at high priority for treatment

  Liz Highleyman / 07 January 2015

  An estimated 813,000 people with diagnosed hepatitis C in the US have undergone liver disease staging and meet the 'highest' or 'high' priority criteria for immediate treatment, according to an analysis presented ...

• Prognosis and disease progression

  Many hepatitis C patients with cirrhosis or advanced fibrosis face liver failure and liver cancer

  Liz Highleyman / 07 January 2015

  Nearly one-third of chronic hepatitis C patients with liver cirrhosis and 12% with advanced fibrosis progressed to decompensation within five years, and 23% and 11%, respectively, died, according to a study presented ...

• Cirrhosis

  Sofosbuvir/ledipasvir cures most previously treated hepatitis C patients with cirrhosis

  Liz Highleyman / 07 January 2015

  Difficult-to-treat hepatitis C patients with liver cirrhosis who were not cured with a prior course of first-generation HCV protease inhibitors had a sustained response rate of 96-97% when re-treated with sofosbuvir/ledipasvir with ribavirin ...